198 related articles for article (PubMed ID: 20660537)
1. Darapladib: an emerging therapy for atherosclerosis.
Corson MA
Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):241-8. PubMed ID: 20660537
[TBL] [Abstract][Full Text] [Related]
2. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Riley RF; Corson MA
IDrugs; 2009 Oct; 12(10):648-55. PubMed ID: 19790016
[TBL] [Abstract][Full Text] [Related]
3. Darapladib.
Bui QT; Wilensky RL
Expert Opin Investig Drugs; 2010 Jan; 19(1):161-8. PubMed ID: 20001561
[TBL] [Abstract][Full Text] [Related]
4. Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic.
Suckling KE
Expert Opin Investig Drugs; 2009 Oct; 18(10):1425-30. PubMed ID: 19691442
[TBL] [Abstract][Full Text] [Related]
5. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.
Serruys PW; García-García HM; Buszman P; Erne P; Verheye S; Aschermann M; Duckers H; Bleie O; Dudek D; Bøtker HE; von Birgelen C; D'Amico D; Hutchinson T; Zambanini A; Mastik F; van Es GA; van der Steen AF; Vince DG; Ganz P; Hamm CW; Wijns W; Zalewski A;
Circulation; 2008 Sep; 118(11):1172-82. PubMed ID: 18765397
[TBL] [Abstract][Full Text] [Related]
6. Phospholipase A2 inhibitors.
Garcia-Garcia HM; Serruys PW
Curr Opin Lipidol; 2009 Aug; 20(4):327-32. PubMed ID: 19550325
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).
Tselepis AF; Rizzo M; Goudevenos IA
Curr Pharm Des; 2011 Nov; 17(33):3656-61. PubMed ID: 22074435
[TBL] [Abstract][Full Text] [Related]
8. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.
White H; Held C; Stewart R; Watson D; Harrington R; Budaj A; Steg PG; Cannon CP; Krug-Gourley S; Wittes J; Trivedi T; Tarka E; Wallentin L
Am Heart J; 2010 Oct; 160(4):655-61. PubMed ID: 20934559
[TBL] [Abstract][Full Text] [Related]
9. Darapladib for the treatment of cardiovascular disease.
Campos CM; Suwannasom P; Koenig W; Serruys PW; Garcia-Garcia HM
Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):33-48. PubMed ID: 25521799
[TBL] [Abstract][Full Text] [Related]
10. Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
Rosenson RS
Curr Opin Lipidol; 2010 Dec; 21(6):473-80. PubMed ID: 20739882
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?
Boekholdt SM; de Winter RJ; Kastelein JJ
Circulation; 2008 Sep; 118(11):1120-2. PubMed ID: 18779454
[No Abstract] [Full Text] [Related]
12. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker.
Toth PP; McCullough PA; Wegner MS; Colley KJ
Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):425-38. PubMed ID: 20222820
[TBL] [Abstract][Full Text] [Related]
13. Utility of Lp-PLA2 in lipid-lowering therapy.
Racherla S; Arora R
Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
[TBL] [Abstract][Full Text] [Related]
14. Phospholipase A2 enzymes and the risk of atherosclerosis.
Rosenson RS; Hurt-Camejo E
Eur Heart J; 2012 Dec; 33(23):2899-909. PubMed ID: 22802388
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target.
Packard CJ
Curr Opin Cardiol; 2009 Jul; 24(4):358-63. PubMed ID: 19417639
[TBL] [Abstract][Full Text] [Related]
16. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
17. Editorial: why inhibition of lipoprotein-associated phospholipase A2 has the potential to improve patient outcomes.
White H
Curr Opin Cardiol; 2010 Jul; 25(4):299-301. PubMed ID: 20485161
[TBL] [Abstract][Full Text] [Related]
18. Reduction in Vasa Vasorum Angiogenesis by Lp-PLA2 Selective Inhibitor Through The HIF-1α and VEGF Expression Under Dyslipidemic Conditions in Atherosclerosis Pathogenesis.
Heriansyah T; Nafisatuzzamrudah N; Aini FN; Ridwan M; Primardhika RF; Wijayanti M; Bekti RS; Wihastuti TA
Cardiovasc Hematol Agents Med Chem; 2018; 16(2):114-119. PubMed ID: 30394217
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Wilensky RL; Macphee CH
Curr Opin Lipidol; 2009 Oct; 20(5):415-20. PubMed ID: 19667981
[TBL] [Abstract][Full Text] [Related]
20. Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target?
McCullough PA
Curr Atheroscler Rep; 2009 Sep; 11(5):334-7. PubMed ID: 19664375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
